CASTLE BIOSCIENCES, INC. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
CASTLE BIOSCIENCES, INC. (CSTL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2021-03-11
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2020-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2019-09-30 was 290.00K shares.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2018-09-30 was 0.00 shares.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2019 was 74.00K shares.
- CASTLE BIOSCIENCES, INC. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2018 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month as first filed | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | 0.00 shares 10-K · filed 2021-03-11 | ||||
| 2020-09-30 | 0.00 shares 10-Q · filed 2020-11-09 | 0.00 shares 10-Q · filed 2020-11-09 | |||
| 2019-12-31 | 74.00K shares 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | 290.00K shares 10-Q · filed 2020-11-09 | 290.37K shares 10-Q · filed 2019-11-12 | 98.00K shares 10-Q · filed 2020-11-09 | 97.85K shares 10-Q · filed 2019-11-12 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-12 | 0.00 shares 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B |